title: Modulation of multidrug resistance by cepharanthine in fresh human gastrointestinal tumor cells.
abstract: Resistance to doxorubicin (DOX) is mainly due to the effect of P-glycoprotein encoded by the multidrug resistance (MDR) gene. Cepharanthine (CEP) has been shown to circumvent multidrug resistance in P-glycoprotein-expressing cell lines. In the present study, we investigated the augmentation of DOX sensitivity by CEP using an MTT assay, and assessed the correlation between DOX sensitivity and P-glycoprotein expression by flow cytometry, in highly purified fresh human tumor cells obtained from 73 cancer patients. DOX sensitivity was decreased in proportion to P-glycoprotein expression. The cytotoxicity of DOX was increased by CEP in tumor cells possessing low DOX sensitivity. Moreover, there was a significant correlation between the effect of CEP on cytotoxicity and P-glycoprotein expression. Thus, CEP might be able to circumvent DOX resistance in cancer patients.
authors.affiliation: Second Department of Surgery, Wakayama Medical School, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Hotta
authors.forename: H
authors.initials: H
authors.lastname: Tanimura
authors.forename: H
authors.initials: H
authors.lastname: Yamaue
authors.forename: M
authors.initials: M
authors.lastname: Iwahashi
authors.forename: M
authors.initials: M
authors.lastname: Tani
authors.forename: T
authors.initials: T
authors.lastname: Tsunoda
authors.forename: M
authors.initials: M
authors.lastname: Tamai
authors.forename: K
authors.initials: K
authors.lastname: Noguchi
authors.forename: S
authors.initials: S
authors.lastname: Mizobata
authors.forename: K
authors.initials: K
authors.lastname: Arii
authors.forename: H
authors.initials: H
authors.lastname: Terasawa
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000096:biosynthesis / Q000187:drug effects; D000470:Alkaloids / Q000494:pharmacology*; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D044182:Benzylisoquinolines; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000503:physiopathology; D004317:Doxorubicin / Q000008:administration & dosage; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000503:physiopathology*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000503:physiopathology; D052117:Benzodioxoles
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000470:Alkaloids; D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D044182:Benzylisoquinolines; D004317:Doxorubicin; C006947:cepharanthine; D052117:Benzodioxoles